Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


Roche Tries Again With Failed Huntington’s Drug Tominersen

Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.

Rare Diseases Clinical Trials Companies

Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration

The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.

Deals Metabolic Disorders Companies

Stock Watch: When Governments Step In

Typically, state intervention in pharmaceuticals is aimed at drug cost control which, if taken to extremes, can border on nationalism.

Stock Watch Advisory Committees Approvals

Scrip Podcast

Insights and perspectives on commercial, R&D,

deal-making and business strategy developments.

More Podcasts


Recent Tweets from Scrip


 

Infographics

Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Commercial Financing

Breast Cancer Trial Enrollment Illustrates Diversity Challenge

INFOGRAPHIC: Data on industry-sponsored breast cancer studies posted on ClinicalTrials.gov shows how much work remains for drug makers to ensure their studies enroll diverse populations.

Diversity & Inclusion Clinical Trials

Alzheimer’s Disease: Many Failures Before One Success

For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been. 

Approvals Clinical Trials

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy

Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.

M & A Neurology

Finance Watch: SPACs Lose Their Luster As Difficulties Mount

Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma. 

Financing Business Strategies

Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus

The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.

Companies Business Strategies

Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics

The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.

Commercial Strategy

Venture Investors See China Remaining Attractive Despite High Valuations

In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”

China Financing

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Deal Watch Business Strategies
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space

The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.

Approvals Dermatology

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Approvals Dermatology

Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

Reimbursement Market Access
See All

Research & Development

Set Alert for Research & Development

Latest From Research & Development

Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic

The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.

Financing Deals

Hal Barron To Depart GSK To Head Up New Biotech

As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.

Companies Research & Development

China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle

Gene therapies for conditions ranging from hemophilia to retinal diseases are blossoming in China and the race in which the winner may take all is on. Driven by ready investors, the field is on the cusp of becoming the latest innovation battleground in the country, while some developers are already moving ahead in the US.

China Gene Therapy
See All
UsernamePublicRestriction

Register